

08 November 2013

Biofrontera publishes interim report for the 3rd quarter of 2013

Leverkusen, Germany – Biofrontera AG (DSE: B8F) has today published its interim report for the third quarter of 2013 on the corporate webpage. The report focuses on the company's development; detailed financial figures are not being published at the end of this period.

For further information please contact:

Thomas Schaffer, CFO

+ 49 214 87632 0
+ 49 214 87632 90
t.schaffer@biofrontera.com

Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany

The ongoing commercial year is characterized by the marketing of Ameluz[®], Biofrontera's prescription drug for the treatment of actinic keratosis. Since February 2012 Ameluz[®] is distributed in Germany through Biofrontera's own sales force. Biofrontera achieved a significant increase in revenues from product sales compared to the same period in the previous year. In the first nine months of 2013, 15,633 tubes of Ameluz[®] were sold, compared to 9,250 tubes last year. Product sales for the first nine months 2013 were TEUR 1.868, compared to TEUR 1,103 in the comparable period of the previous year, representing a 69% increase. In the first months of the year 2012 license deals were closed for several European countries, resulting in one-time payments of TEUR 1,550 in addition to the product sales. The marketing agreements closed this year covered smaller countries and did not include upfront payments since higher transfer prices were agreed upon.

During the reporting period Ameluz[®] was launched in Spain by our regional representative Allergan in an impressive educational event for Spanish dermatologists in Madrid. Ameluz[®] is reimbursed by 100% in Spain. Spain is one of the largest PDT-markets in Europe and Biofrontera expects positive effects for its further revenue growth outside Germany.

The clinical studies for the expansion of the approved indications for Ameluz[®] and the registration in the USA were also initiated in the reporting period. Patient recruitment has already started in three clinical trials, while the fourth trial is in the approval process. Total research and development expenses amounted to TEuro 1,950 in the first nine months of the year.

News Release

About Biofrontera AG

Biofrontera Pharma GmbH is a wholly-owned subsidiary of Biofrontera AG. The Biofrontera group aims at attending and treating the skin, recognizing the aesthetic needs of a person's visual reflection. Biofrontera is listed at the regulated market of the Frankfurt stock exchange under the symbol B8F and the ISIN number DE0006046113.

For further information please contact:

Thomas Schaffer, CFO

+ 49 214 87632 0
+ 49 214 87632 90
t.schaffer@biofrontera.com

Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany

www.biofrontera.com

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.